Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
摘要：
Covering: up to 2008 Ecteinascidins are marine natural products consisting of two or three linked tetrahydroisoquinoline subunits and an active carbinolamine functional group. Their potent antiproliferative activity against a variety of tumor cells makes them attractive candidates for development as anticancer agents. The lead compound, Yondelis(trabectedin, ET-743) is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Positive results of a large randomized Phase III clinical trial in ovarian cancer have recently been presented. The low amounts present in its natural source, the tunicateEcteinascidia turbinata, made it necessary to develop efficient synthetic procedures. The original total synthesis is reviewed as well as a new semisynthetic process from the readily available cyanosafracin B, which has solved the supply problem.
展开
DOI：
10.1039/b808331m
被引量：
年份：
2009
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
